
Insights
- Articles
Digital dose: using social media and online platforms to market and sell medicines and medical products
25 Sept 2024Recent attention has focused on the relationship between social media and medical products, as healthcare professionals noted an increase in influencers marketing unlicensed versions of the weight loss drug, semaglutide (branded as Ozempic and Wegovy).
- Articles
Key Deadlines for the Windsor Framework: what you need to know about medicine regulations
25 Sept 2024Marketing authorisation holders (MAHs) are required to take specific actions regarding their product licenses in Northern Ireland (NI) and Great Britain (GB) by 30 September 2024 to avoid potential regulatory complications.
- Articles
How's it going for pharma SMEs in the EU?
04 Sept 2024In the EU, there are regulations - lots of them. There's even a specific regulation for micro, small and medium-sized enterprises (SMEs) in the pharma sector. The EU is seeking opinions on support for pharmaceutical SMEs.
- Articles
£100 million boost to quantum hubs to aid life sciences innovations
04 Sept 2024The UK Government has recently allocated substantial funding of over £100 million to support five new quantum research hubs across the UK.
- Articles
Long term agreements still apply even when things change
03 Sept 2024When a licensee entered into a trade mark licence for 25 years and decided five years in that they did not want to use the trade mark any more, they were still required to pay the large minimum royalties, the Court of Appeal has ruled.
- Articles
PING 2024 round-up - 'AI in pharma - Threat or opportunity?'
16 Jul 2024Over a month has passed since the 2024 PING conference, providing invaluable insights into the uptake of AI in Pharma, its transformational promise, and the accompanying risks and pitfalls. Below is a summary of our key takeaways.